NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
33 trialsNCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT05155189 2026-01-21
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1 Recruiting
NCT07343791 2026-01-15
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07213570 2025-12-17
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06902246 2025-12-02
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT05113368 2025-08-21
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT07100392 2025-08-17
LEAF-02
Fudan University
Phase 2 Recruiting
NCT07003022 2025-06-04
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
Phase 2 Recruiting
NCT06949982 2025-05-04
x-МАР
Pavlov First Saint Petersburg State Medical University
Phase 2 Recruiting
NCT06911684 2025-04-23
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
Phase 2 Recruiting
NCT06930118 2025-04-16
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT06275919 2025-03-13
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2 Recruiting
NCT04503694 2025-03-05
REGINA
Jules Bordet Institute
Phase 2 Recruiting
NCT05057052 2025-02-27
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
Phase 2 Recruiting
NCT06456515 2025-02-17
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
Phase NA Recruiting
NCT06829355 2025-02-17
THYMI
Beijing Friendship Hospital
Phase 2 Recruiting
NCT06425133 2024-12-24
CARE
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT05462613 2024-12-20
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
Phase 2/3 Recruiting
NCT05963490 2024-09-24
SLOT
Fudan University
Phase 2 Recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT05985109 2023-10-26
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT06099821 2023-10-26
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05970705 2023-08-01
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University
Phase 2 Recruiting
NCT05794971 2023-05-15
RIDER
Sun Yat-sen University
Phase 3 Recruiting